Cynosure, Inc. expected to Report Fiscal Year 2009 Results on February 8, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).

Cynosure Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported revenue of $17,937,000, loss from operations of $3,341,000, loss before income taxes of $2,887,000, net loss of $1,915,000 or $0.15 diluted per share compared with revenue of $38,209,000, income from operations of $4,927,000, income before income taxes of $5,051,000, net income of $3,163,000 or $0.25 diluted per share over the same period last year. Non-GAAP loss from operations of $1,877,000, non-GAAP net loss of $911,000 or $0.07 diluted per share against non-GAAP income from operations of $7,023,000, non-GAAP net income of $4,709,000 or $0.37 diluted per share for the same period last year. The decrease in revenues from the third quarter of 2008 reflected the downturn in global economic conditions and the effects of a highly restrictive credit environment in North America. The decrease in sequential revenue reflected the typical seasonality of the third quarter. Total operating expenses decreased as the company maintained its focus on reducing costs in response to the current economic climate. For the nine months, the company reported revenue of $53,566,000, loss from operations of $14,568,000, loss before income taxes of $13,409,000, net loss of $8,260,000 or $0.65 diluted per share compared with revenue of $114,167,000, income from operations of $17,618,000, income before income taxes of $19,604,000, net income of $12,692,000 or $0.99 diluted per share over the same period last year. Non-GAAP loss from operations of $9,458,000, non-GAAP net loss of $5,312,000 or $0.42 diluted per share against non-GAAP income from operations of $23,281,000, non-GAAP net income of $16,306,000 or $1.27 diluted per share for the same period last year.

Cynosure, Inc. announced the introduction of Smartlipo Triplex(TM), the world's first laser lipolysis solution featuring three wavelengths that combine to deliver high-powered fat absorption and tissue tightening through tissue coagulation. Smartlipo Triplex will be formally launched at Plastic Surgery 2009, the American Society of Plastic Surgeons Annual Meeting, which will be held October 23-27 in Seattle. Smartlipo Triplex adds a 1440 nm wavelength to the MPX generation of the product, and employs Cynosure's patented MultiPlex technology to combine the benefits of three wavelengths in one laser output. MultiPlex technology enables two wavelengths to be fired sequentially, creating a blended thermal and photomechanical effect that efficiently liquefies fat and tightens skin through collagen remodeling. Smartlipo Triplex is equipped with SmartSense with ThermaGuide, the latest in Cynosure's proprietary family of intelligent energy delivery systems. SmartSense with ThermaGuide is designed to work in harmony with the laser. It continually detects the temperature under the skin and controls the output of energy. This helps to ensure that the treatment area remains within a safe and optimal temperature range for fat removal and tissue tightening through tissue coagulation.